Bristol Myers Squibb And Rayzebio Announced Expiration Of Waiting Period Under Hart-scott-rodino Antitrust Improvements Act Of 1976, In Connection With Bristol Myers Squibb's Previously Announced Deal To Acquire Rayzebio For $62.50/Shares On Feb 9
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (BMY) and Rayzebio have announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, related to BMY's deal to acquire Rayzebio for $62.50 per share, announced on February 9.
February 12, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's acquisition of Rayzebio is progressing as the regulatory waiting period has expired. The deal is valued at $62.50 per share.
The expiration of the Hart-Scott-Rodino waiting period is a significant regulatory step forward for Bristol Myers Squibb's acquisition of Rayzebio, indicating reduced regulatory hurdles ahead. This development is likely to be viewed positively by investors, potentially leading to a short-term uptick in BMY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90